Journal of Neural Transmission

Papers
(The median citation count of Journal of Neural Transmission is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Alterations in metabolites in the anterior cingulate cortex and thalamus and their associations with pain and empathy in patients with chronic mild pain: a preliminary study94
Facets of movement disorders– a tribute to Heinz Reichmann92
Proteinopathies: molecular mechanisms and diagnostic perspectives67
Eye movement study in essential tremor patients and its clinical correlates62
Current perspectives on brain circuits involved in food addiction-like behaviors60
Do demographic and clinical features and comorbidities affect the risk of spread to an additional body site in functional motor disorders?58
A wearable device-enabled therapeutic approach to improve joint attention in autism spectrum disorder: a prospective pilot study56
Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes54
Pathogenesis of Parkinson’s disease: from hints from monogenic familial PD to biomarkers53
Stress enhances heartbeat-evoked potentials, independent of continuous or intermittent theta burst stimulation of the interoceptive brain network targeting the right supramarginal gyrus: a preliminary52
Dopamine agonists in the treatment of Parkinson's disease: the show must go on46
Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up46
Distinct gait dimensions are modulated by physical activity in Parkinson's disease patients41
Celebrating the career of professor Zdravko Lacković: a life in neuroscience, pharmacology, and discovery41
Sitagliptin attenuates L-dopa-induced dyskinesia by regulating mitochondrial proteins and neuronal activity in a 6-OHDA-induced mouse model of Parkinson’s disease40
A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response:40
Movement disorders associated with diarrhoea39
Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson’s disease38
Contrasting features between Tourette syndrome and secondary tic disorders37
Bradykinesia and rigidity modulated by functional connectivity between the primary motor cortex and globus pallidus in Parkinson’s disease36
Non motor Parkinson: subtypes, biomarkers, stepped care and a journal!36
Camillo Golgi’s contributions to the anatomic basis of sensitivity in tendons33
Botulinum toxin and conservative treatment strategies in people with cervical dystonia: an online survey32
Unusual delayed and prolonged arm weakness and atrophy following botulinum toxin injection for musician’s cramp: case report31
The spectrum of behavioral disorders in amyotrophic lateral sclerosis: current view31
Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research30
Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer’s disease therapy30
COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion28
The role of immune and inflammatory-related indicators in cognitive dysfunction and disease severity in patients with parkinson’s disease27
Reduced vagal activity in borderline personality disorder is unaffected by intranasal oxytocin administration, but predicted by the interaction between childhood trauma and attachment insecurity27
Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study27
Association between autonomic dysfunction with motor and non-motor symptoms in patients with Parkinson's disease26
Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 201626
Unravelling head tremor mechanisms: insights from speech analysis in essential tremor and cervical dystonia25
Constipation and pain in Parkinson’s disease: a clinical analysis24
A call to action: revitalizing the German parkinson’s research ecosystem post-pandemic24
The pathobiology of depression in Huntington’s disease: an unresolved puzzle24
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease23
Impact of APOE and MAPT genetic profile on the cognitive functions among Amyotrophic Lateral Sclerosis Tunisian patients23
Illness perceptions in pre-operative Parkinson’s disease patients22
MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy21
Regulation of circadian gene activity in fibroblasts from ADHD patients through Rosiglitazone: a pilot study21
Insulin resistance: fueling oxidative stress and neurodegeneration20
The relationship of early life adversity and physiological synchrony within the therapeutic triad in horse-assisted therapy20
The corticospinal tract in multiple sclerosis: correlation between cortical excitability and magnetic resonance imaging measures19
Axial postural abnormalities and pain in Parkinson’s disease18
Old problems, new solutions: harnessing technology and innovation in Parkinson’s disease—evidence and experiences from Thailand18
Update on sleep disorders in advanced Parkinson’s disease: a narrative review17
Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice17
Drug repurposing and new drug targets: perspectives for novel treatment options in mental health disorders17
The brainstem reticular formation pivots abnormal neural transmission in the course of Anorexia Nervosa17
Sleep disorders among frontline nurses after the COVID-19 outbreak: a large-scale cross-sectional study17
Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice16
Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration16
Proteinopathies associated to repeat expansion disorders16
Small intestinal bacterial overgrowth in Alzheimer’s disease16
The two-network framework of number processing: a step towards a better understanding of the neural origins of developmental dyscalculia16
Potentially inappropriate medications according to PRISCUS list and FORTA (Fit fOR The Aged) classification in geriatric psychiatry: a cross-sectional study15
MAOA methylation is associated with impulsive and antisocial behaviour: dependence on allelic variation, family environment and diet15
Advanced therapy in advanced Parkinson’s disease: money’s too tight to mention15
Autism Spectrum Disorder and auditory sensory alterations: a systematic review on the integrity of cognitive and neuronal functions related to auditory processing14
A historical review of multiple system atrophy with a critical appraisal of cellular and animal models14
Atrophy of cerebellar lobule VI and primary motor cortex in cervical dystonia - a region of interest-based study14
Psychological, neuroendocrine and inflammatory stress responses in women after miscarriage or stillbirth: investigating early psychobiological adaptations to potential traumatic events14
Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease14
Serum glial fibrillary acidic protein is elevated in early-stage late-onset essential tremor and associated with tremor progression14
Neuroscience and addiction research: current advances and perspectives14
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone14
Language in autism: domains, profiles and co-occurring conditions14
Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study14
Prenatal exposure to morphine enhances excitability in locus coeruleus neurons14
In situ stoichiometry amounts of p62 and poly-ubiquitin exceed the increase of alpha-synuclein during degeneration of catecholamine cells induced by autophagy inhibition in vitro14
Sexual dysfunction in men with young onset Parkinson's disease13
Increased hair cortisol in mothers of children with ADHD symptoms and psychosocial adversity background13
Exploring developmental trajectories throughout adolescence of children with autism spectrum disorder without intellectual disability13
The natural course of idiopathic cervical dystonia13
Sex differences in schizophrenia: a longitudinal methylome analysis13
The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease12
Reduced cerebrospinal fluid taurine is associated with nigrostriatal dopaminergic deficits in drug-naïve Parkinson’s disease12
Tips and tricks in tremor treatment12
The impact of cerebral vasomotor reactivity on cerebrovascular diseases and cognitive impairment12
Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA12
Perceived social support declines after deep brain stimulation surgery in patients with Parkinson’s disease12
Issues for patchy tissues: defining roles for gut-associated lymphoid tissue in neurodevelopment and disease12
Exploring transferability in psychiatric interventions: a conceptual framework12
Superoxide dismutase isozymes in cerebral organoids from autism spectrum disorder patients12
From the tyrosine hydroxylase hypothesis of Parkinson’s disease to modern strategies: a short historical overview12
Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS11
Maternal separation and its developmental consequences on anxiety and parvalbumin interneurons in the amygdala11
Unveiling the link between chronic pain and misuse of opioids and cannabis11
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide11
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease11
Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes11
Clinimetrics of the Italian version of the Montreal Cognitive Assessment (MoCA) in adult-onset idiopathic focal dystonia11
Oligodendrocytes matter: a review of animal studies on early adversity11
Writing tremor in Parkinson’s disease: frequency and associated clinical features11
Therapeutic use of medical Cannabis in neurological diseases: a clinical update11
Patterns of striatal dopamine depletion and motor deficits in de novo Parkinson’s disease11
Usability of the digit-tracking technique in a geriatric population of inpatients with and without neurocognitive disorders: The DIGICOG-start study10
A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A10
Neuromarkers in addiction: definitions, development strategies, and recent advances10
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations10
Treatment; Moussa B.H. Youdim10
Protein clearance strategies for disease intervention10
If you can't be with the one you love, love the one you're with (C, S, N & Y)10
Plasma prolactin and symptoms of schizophrenia10
Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes10
Depression in dementia with Lewy bodies: a critical update10
Correction: The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies10
Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels10
High-dose glucocorticoids in COVID-19 patients with acute encephalopathy: clinical and imaging findings in a retrospective cohort study10
RNA sequencing of the thalamus and rostral ventral medulla in rats with chronic orofacial pain10
Mild cognitive impairment in amyotrophic lateral sclerosis: current view10
Depression and anxiety in multiple sclerosis. Review of a fatal combination10
Catecholamines and Parkinson’s disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview10
MEF2C gene variations are associated with ADHD in the Chinese Han population: a case–control study9
A smartphone-based tapping task as a marker of medication response in Parkinson’s disease: a proof of concept study9
Polymorphisms of COMT and CREB1 are associated with treatment-resistant depression in a Chinese Han population9
Mediating roles of attention-deficit/hyperactivity disorder symptom severity and self-control on the relationship between adverse childhood experiences and adult aggression9
Differential diagnosis of Huntington’s disease− neurological aspects of NKX2-1-related disorders9
Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s disease9
Correlation between the MNCD classification-based staging of Parkinson’s disease and quality of life: a cross-sectional study9
The akinetic crisis in Parkinson´s disease- the upper end of a spectrum of subacute akinetic states9
Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer’s disease9
The heterogeneity of Parkinson’s disease9
The effect of recombinant botulinum neurotoxin A on neuropathic pain in the spared nerve injury mouse model9
Environmental opportunities facilitating cognitive development in preschoolers: development of a multicriteria index9
Advanced is advanced is advanced is advanced9
SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t9
The pathobiological basis of depression in Parkinson disease: challenges and outlooks9
Neurogenic orthostatic hypotension in Parkinson’s disease: is there a role for locus coeruleus magnetic resonance imaging?8
From parents to children: associations of traffic risks with impulsivity, family relationships and serotonin transporter genotype8
Psychotherapies in opioid use disorder: toward a step-care model8
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone8
Cognition and Activity of Daily Living Function in people with Parkinson’s disease8
Drug interactions in a sample of inpatients diagnosed with cannabis use disorder8
Locus Coeruleus magnetic resonance imaging: a comparison between native-space and template-space approach8
Mild cognitive impairment in Huntington’s disease: challenges and outlooks8
Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?8
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice8
Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson’s disease8
Driving innovation in addiction treatment: role of transcranial magnetic stimulation8
Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease8
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome8
Facial emotion recognition deficits are associated with hypomimia and related brain correlates in Parkinson’s disease8
The sex-specific relationship of ghrelin and cognition in Chinese han first-episode drug-naive major depressive disorder8
The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study8
The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates8
Iron and copper ions accelerate and modify dopamine oxidation to eumelanin: implications for neuromelanin genesis8
Interrater reliability of motor severity scales for hemifacial spasm8
Mild cognitive impairment in multiple system atrophy: a brain network disorder8
Association of polygenic risk scores, traumatic life events and coping strategies with war-related PTSD diagnosis and symptom severity in the South Eastern Europe (SEE)-PTSD cohort8
Reduced interleukin-6 stress reactivity in male physicians with occupational burnout7
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?7
Bioinformatics approach reveals the critical role of the NOD-like receptor signaling pathway in COVID-19-associated multiple sclerosis syndrome7
Association between alcohol consumption and mortality in Parkinson’s disease7
Concomitant pathologies and their impact on Huntington’s disease. A brief review of current evidence7
Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network7
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease7
Insights into insulin signalling and oxidative stress in the Tg2576 mouse model of familial Alzheimer’s disease: effects of chronic oral galactose administration7
Vascular parkinsonism: an update7
Plasma concentrations of anti-inflammatory cytokine TGF-β are associated with hippocampal structure related to explicit memory performance in older adults7
Botulinum toxin therapy: past, present and future developments7
Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review7
GBA-associated PD: chances and obstacles for targeted treatment strategies7
The impact of short-term blood pressure variability on cognitive decline in Parkinson’s disease patients without co-morbidities7
Parkinson's Disease Multidisciplinary Complex Therapy (PD-MCT): appreciation of its current function for the treatment of people with Parkinson’s disease in Germany and the needs of future development7
Time-course of decline in different cognitive domains in Parkinson’s disease: a retrospective study7
Neurodevelopmental disorders (NDD) without boundaries: research and interventions beyond classifications7
Identification of DAGLB variants in Japanese early-onset Parkinson’s disease7
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?7
Genetic and environmental mouse models of autism reproduce the spectrum of the disease7
A structured framework for emotion-cognition dynamics: Implications for assessment and intervention7
Nicotinic regulation of microglia: potential contributions to addiction7
Probing the properties of PTEN specific botulinum toxin type E mutants7
Diagnostic and therapeutic challenges in PD-associated non-motor symptoms: the roles of neurologists and consultant physicians7
Clinical correlates of pareidolias and color discrimination deficits in idiopathic REM sleep behavior disorder and Parkinson’s disease6
New trends in the research of psychiatric and neurodegenerative diseases: a tribute to Melita Salkovic-Petrisic6
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease6
Correction to: Common network effect‑patterns after monoamine reuptake inhibition in dissociated hippocampus cultures6
Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 20166
Sex- and age-specific prevalence and risk factors of depressive symptoms in Parkinson’s disease6
Is the vertex a good control stimulation site? Theta burst stimulation in healthy controls6
Deep brain stimulation in progressive supranuclear palsy: a dead-end story? A narrative review6
MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia6
Motor and non-motor fluctuations in Parkinson’s disease: the knowns and unknowns of current therapeutic approaches6
Predisposing factors to pattern change in cervical dystonia6
Disease modification in Parkinsonism: obstacles and ways forward6
Essential tremor plus rest tremor: current concepts and controversies6
Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis6
Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review6
Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study6
Insulin signaling disruption exacerbates memory impairment and seizure susceptibility in an epilepsy model with Alzheimer’s disease-like pathology6
Correction: Revolutionizing our understanding of Parkinson’s disease: Dr. Heinz Reichmann’s pioneering research and future research direction6
A cross-language speech model for detection of Parkinson’s disease6
The relationship between sphingomyelin and ceramide levels and soft neurological signs in ADHD6
Temporal onset of non-motor symptoms and the body-first/brain-first dichotomy in Parkinson’s disease: a cross-sectional single center experience5
Editorial for Emeritus Professor Yoshikuni Mizuno5
Neurobiological mechanisms of dialectical behavior therapy and Morita therapy, two psychotherapies inspired by Zen5
Prof. DDr. Gregor K. Wenning (1964–2024)5
Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress5
Oculometric measures as a tool for assessment of clinical symptoms and severity of Parkinson’s disease5
Viruses, parkinsonism and Parkinson’s disease: the past, present and future5
The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder5
Treadmill training and physiotherapy similarly improve dual task gait performance: a randomized-controlled trial in Parkinson’s disease5
Prevalence and impact of comorbidities in amyotrophic lateral sclerosis5
Behavioral disorders in Parkinson disease: current view5
COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study5
Mitochondrial dysfunction in Parkinson’s disease5
Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study5
Steroid hormone pathways, vitamin D and autism: a systematic review5
Current trends in basic research on Parkinson’s disease: from mitochondria, lysosome to α-synuclein5
Brain instability in dynamic functional connectivity in schizophrenia5
Neural bases characterizing chronic and severe upper-limb motor deficits after brain lesion5
Excessive psychological stress preceding the onset of idiopathic cervical dystonia5
ADHD and associated psychopathology in older adults in a German community sample5
Special issue in honor of Peter Riederer at the occasion of his 80th birthday5
Multilevel and multimodal biobehavioral methods in the study of stress, trauma, and resilience: a systems approach5
Premorbid de novo artistic creativity in frontotemporal dementia (FTD) syndromes5
Clinical and kinematic characterization of parkinsonian soft signs in essential tremor5
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry5
The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies5
The specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP-intoxicated mice5
Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies4
Declining incidence of Parkinson’s disease in Israel (2002–2021)4
The ‘α-synucleinopathy syndicate’: multiple system atrophy and Parkinson’s disease4
Elevated levels of cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 in multiple system atrophy: a marker of disease-associated microglial activation4
Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy (MT); comparison of three established psychotherapies and possible common neural mechanisms of psychothe4
Action impulsivity and attention deficits in patients at an early stage of Huntington disease4
Deep brain stimulation for psychostimulant use disorders4
Modulatory effect of olanzapine on neuronal nitric oxide synthase (nNOS) expression in the rat striatum4
Renaming of Hallervorden–Spatz disease: the second man behind the name of the disease4
Possible improvement of social adjustment after subthalamic deep brain stimulation in people with Parkinson’s disease? A systematic review and meta-analysis4
Dopamine denervation in the functional territories of the striatum: a new MR and atlas-based 123I-FP-CIT SPECT quantification method4
The effectiveness of non-invasive brain stimulation in treatment of major depressive disorder (MDD): a systematic review and transfer analysis4
The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models4
Peter Riederer, a translational neurobiochemist4
Approaching therapy of Alzheimer’s disease via the antidiabetic drug liraglutide—a study with streptozotocin intracerebroventricularly treated Wistar rats4
Correction to: Proteinopathies: molecular mechanisms and diagnostic perspectives4
Neuroplasticity in Parkinson’s disease4
Spasmodic dysphonia: the need for a combined neurological and phoniatric approach4
More than fear? Brain activation patterns of dental phobic patients before and after an exposure-based treatment4
Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pha4
Genetic testing for Parkinson’s disease in clinical practice4
Altered domain-specific striatal functional connectivity in patients with Parkinson’s disease and urinary symptoms4
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study4
Challenges in the treatment of Tourette syndrome in the Philippines4
Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes4
Glutathione S-transferase polymorphisms (GSTM1/GSTT1) outcomes in clinical profile and treatment responsiveness among Tunisian cohort of Parkinson’s disease4
Neuroscience in addiction research4
0.063677072525024